TechNavio today launched its report Global Inhaled Antibiotics Market 2011“2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers™ understanding of the key trends impacting the growth of this market.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, Inhaled medicines travel directly to the lungs, where they are required, leading to a better and faster cure than oral or injected treatment. Patients suffering from cystic fibrosis can be given antibiotic treatments via the oral, intravenous, and inhaled routes. It has also been observed that patients suffering from chronic sinus infections who have not benefited from standard drugs or surgery experience significant improvement by inhaling antibiotics.
According to the report, the global market is witnessing a trend of increasing number of mergers and acquisitions. As growth in the sales of infectious disease treatment is significantly increasing in the Healthcare sector, major pharmaceutical and biopharmaceutical companies are focusing on the Global Inhaled Antibiotics market for increasing revenue and market share through mergers and acquisitions.
Further, the report also discusses various challenges impacting the growth of this market including the stringent government approvals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/global-inhaled-antibiotics-market-2011-2015
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Report “ Global Inhaled Antibiotics Market 2011“2015
